VANCOUVER, July 20 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced today that the Company will present the blood vessel regeneration effects of its novel compound CTCE-0324 at the 2006 Gordon Research Conference on Chemotactic Cytokines to be held in Aussois, France during September 18-22, 2006.
The Company has developed a new pre-clinical drug candidate that causes blood vessel regeneration once injected locally in the body. In a series of in-vitro and in-vivo experiments, the Company has demonstrated that CTCE-0324 enhances the survival of endothelial cells (essential components of existing blood vessels), stimulates the differentiation of individual endothelial cells into coordinated tube-like structures (mini blood vessels), and induces new blood vessels to sprout from existing ones using cell culture systems. The Company also demonstrated, by way of injection in an animal model, that CTCE-0324 mobilizes stem cells and induces the formation of new blood vessels. This work further underscores the potential of CTCE-0324, thus providing the framework for its continued development as a potential novel therapy for the treatment of vascular diseases.
There are a number of vascular diseases including peripheral and coronary arterial disease affecting approximately 10% of Americans. Currently there is very limited treatment available and often these patients require some form of surgical intervention, including limb amputation or open heart surgery. Collateral blood vessel formation is a natural response to blood vessel blockage, however blood vessel formation is often suboptimal or impaired, especially in the elderly, diabetics, obese and atherosclerosis patients. Therefore, the development of drugs that stimulate new blood vessel growth is of critical importance.
CTCE-0324 is a protein-based drug of Chemokine Therapeutics that has the potential to revolutionize the way vascular diseases are treated today. Local injections of CTCE-0324 may help to restore blood flow through growth and differentiation of primitive cells into blood vessels. Dr. Hassan Salari, Chemokine Therapeutics President and Chief Executive Officer, stated, "Through generation of new vessels from primitive cells already present in the body, the future of blood vessel surgery and heart bypass could be dramatically impacted. The human body has a considerable number of primitive cells including stem cells which we believe can be activated to generate tissues or organs given an appropriate growth factor. This is a profoundly exciting area of study and one in which Chemokine Therapeutics is intent on leading material advances."
About 2006 Gordon Research Conference on Chemotactic Cytokines
The 2006 Gordon Research Conference on Chemotactic Cytokines brings together international academic and industry experts in chemotactic cytokines (or chemokines) to present the latest developments in research and therapeutic applications in this emerging drug class.
About Chemokine Therapeutics Corp.
Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, and stem cells, as well as tissue repair and regeneration. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development. For more information, please visit the Company's website at www.chemokine.net.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT: Elite Financial Communications Group, Chemokine Investor Relations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail: chkt@efcg.net
Chemokine Therapeutics Corp.CONTACT: Elite Financial Communications Group, Chemokine InvestorRelations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail:chkt@efcg.net
